TRT Before Surgery: 2026 Guidelines for Testosterone and Surgical Risk

When Marcus scheduled his hernia repair, his surgeon's office called with strict instructions: "Stop all testosterone immediately and don't restart until we clear you." But when he asked his TRT provider, they referenced new 2026 guidelines showing most men can safely continue testosterone through routine surgeries.

The conflicting advice reflects a major shift in perioperative TRT management. Recent evidence from the TRAVERSE trial and updated surgical society guidelines have fundamentally changed how we approach testosterone replacement therapy before surgery.

The 2026 Paradigm Shift

What Changed

For decades, surgical protocols recommended stopping TRT before any procedure based on theoretical concerns about cardiovascular risk and bleeding complications. The 2026 updates from major surgical societies now distinguish between evidence-based risks and historical precautions.

Previous approach (pre-2026):

• Stop TRT 2-4 weeks before any surgery
• Based on cardiovascular risk concerns
• "Better safe than sorry" philosophy
• Limited evidence supporting broad cessation

New 2026 approach:

• Risk-stratified decision making
• Continue TRT for low-risk procedures
• Stop only when specific risks identified
• Evidence-based protocols from TRAVERSE trial

The TRAVERSE Trial Impact

The landmark 2023 TRAVERSE trial studied 5,246 men on TRT for over 33 months and found no increased cardiovascular events compared to placebo. This definitive safety data eliminated the primary concern driving perioperative TRT cessation.

Key TRAVERSE surgical implications:

• 7.0% cardiovascular events in TRT group vs 7.3% in placebo
• No increased bleeding complications
• No perioperative cardiac events attributed to TRT
• Safe hemodynamic profile during procedures

Current Surgery Categories and TRT Recommendations

Continue TRT (Low Risk)

Outpatient procedures:

• Colonoscopy and endoscopy
• Skin lesion removal
• Cataract surgery
• Arthroscopic joint procedures
• Hernia repair (uncomplicated)
• Vasectomy

Minor inpatient procedures:

• Gallbladder removal (laparoscopic)
• Appendectomy
• Minor orthopedic procedures
• Thyroid surgery
• Most general surgery procedures

Rationale: These procedures carry minimal cardiovascular stress, short duration, and low bleeding risk. TRT continuation doesn't meaningfully impact outcomes.

Consider Stopping TRT (Moderate Risk)

Procedures requiring individual assessment:

• Major abdominal surgery (open procedures)
• Orthopedic procedures with significant bone work
• Reconstructive surgeries lasting >4 hours
• Procedures with expected blood loss >500ml

Decision factors:

• Patient's hematocrit level
• Cardiovascular risk profile
• Surgeon and anesthesiologist comfort level
• Procedure complexity and duration

Stop TRT (High Risk)

Procedures requiring TRT discontinuation:

• Major cardiac surgery (bypass, valve replacement)
• Complex spinal fusion procedures
• Extensive urological reconstruction
• Liver transplantation
• Major cancer resections with extensive lymph node dissection

Specific risks addressed:

• Elevated hematocrit increasing thrombosis risk
• Complex hemodynamic management
• Extended operative times
• High bleeding risk procedures

The Hematocrit Factor

Why Hematocrit Matters

The most legitimate concern with TRT and surgery is polycythemia (elevated red blood cell count). Testosterone can increase hematocrit above normal ranges, potentially increasing blood clotting risk during and after surgery.

Critical hematocrit thresholds:

• Normal range: 38-50% (men)
• TRT monitoring target: <52%
• Surgical concern level: >52%
• High-risk level: >54%

Pre-Surgical Hematocrit Management

If your hematocrit is >52% before planned surgery:

2-4 weeks before surgery:

• Stop TRT temporarily
• Increase hydration
• Consider therapeutic phlebotomy if >54%
• Recheck hematocrit 1 week pre-operatively

Alternative approaches:

• Dose reduction rather than cessation
• More frequent monitoring
• Blood donation (if eligible)

Timing Protocols for TRT Discontinuation

When to Stop

Injectable testosterone (cypionate/enanthate):

• Stop 2-3 weeks before surgery
• Half-life allows gradual decline
• Hematocrit normalizes in 2-4 weeks

Topical testosterone (gels/creams):

• Stop 1-2 weeks before surgery
• Shorter half-life, faster clearance
• Daily application cessation shows rapid effects

Testosterone pellets:

• Cannot be stopped once implanted
• Surgery scheduling around implantation timing
• Effects persist 3-6 months

Monitoring During Cessation

Week 1-2 after stopping:

• Testosterone levels begin declining
• Hematocrit starts normalizing
• Energy levels may decrease

Pre-operative assessment:

• Recheck hematocrit and basic metabolic panel
• Ensure levels are within acceptable ranges
• Clear for surgery when targets met

Post-Operative TRT Resumption

Safe Restart Timeline

Outpatient procedures:

• Resume TRT 48-72 hours post-procedure
• Once bleeding risk has normalized
• When normal activity resumed

Inpatient procedures:

• Wait 1-2 weeks depending on procedure
• Until surgical drains removed
• When cleared for normal activity by surgeon

Major procedures:

• 2-4 weeks post-operatively
• Complete wound healing
• Full mobility and activity clearance

Restart Protocols

Standard resumption:

• Return to pre-surgery dose and schedule
• Monitor for 6 weeks to reassess baseline
• Ensure no surgical complications

Conservative approach:

• Start with 50% of previous dose
• Increase gradually over 4-6 weeks
• Extra monitoring for hematocrit elevation

Communicating with Your Surgical Team

Information to Share

Pre-operative consultation:

• Current TRT protocol and dosing
• Most recent hematocrit and lab values
• Duration of testosterone therapy
• Any history of polycythemia or clotting

Questions to ask:

• Is TRT cessation necessary for this specific procedure?
• What are the specific risks they're concerned about?
• When can TRT be safely resumed?
• Any special monitoring requirements?

Advocating for Evidence-Based Decisions

Many surgeons haven't updated their protocols to reflect 2026 guidelines. Present relevant information:

Share key evidence:

• TRAVERSE trial cardiovascular safety data
• Your most recent hematocrit levels
• 2026 surgical society recommendations
• Low-risk nature of your specific procedure

Collaborate on decision making:

• Request specific risk assessment
• Discuss alternatives to complete cessation
• Consider compromise approaches (dose reduction)

Special Surgical Considerations

Cardiac Surgery

Even with TRAVERSE trial safety data, major cardiac procedures may require TRT cessation due to:

• Complex hemodynamic management
• Use of cardiopulmonary bypass
• Anticoagulation protocols
• Extended operative times

Cardiac surgery TRT protocol:

• Stop 4 weeks pre-operatively
• Ensure hematocrit <48%
• Coordinate with cardiothoracic team
• Resume 4-6 weeks post-operatively

Orthopedic Procedures

Bone surgeries present unique considerations:

• Potential for significant bleeding
• Extended operative positioning
• Post-operative immobilization increasing clot risk

Risk-based approach:

• Simple arthroscopy: Continue TRT
• Joint replacement: Individual assessment
• Spinal fusion: Usually stop TRT
• Complex reconstructive: Stop TRT

Urological Procedures

Prostate and urological surgeries have specific considerations:

• Bleeding risk in vascular tissue
• Traditional concerns about testosterone and prostate
• Post-operative healing requirements

Modern approach:

• Simple procedures: Continue TRT
• TURP and prostate surgery: Individual assessment based on bleeding risk
• Major reconstructive: Stop TRT temporarily

Emergency Surgery Scenarios

Immediate Surgical Needs

When emergency surgery is required, TRT doesn't delay or contraindicate necessary procedures:

Anesthesia considerations:

• Inform anesthesiologist of TRT use
• Provide recent lab values if available
• Modern anesthetic protocols accommodate TRT patients

Surgical management:

• Proceed with necessary emergency surgery
• Monitor for bleeding and clotting appropriately
• Address TRT resumption during recovery

Managing TRT Interruption Symptoms

Expected Effects of Temporary Cessation

Week 1-2:

• Mild energy decrease
• Possible mood changes
• Minimal impact on most men

Week 3-4:

• More noticeable fatigue
• Libido changes
• Motivation decreases

Minimizing Withdrawal Effects

Gradual cessation when possible:

• Reduce dose rather than abrupt cessation
• Maintain portion of physiological levels
• Easier transition and recovery

Supportive measures:

• Maintain exercise routine if possible
• Prioritize sleep and stress management
• Consider short-term energy support supplements

The Future of Perioperative TRT Management

Ongoing Research

Studies currently underway:

• TRT effects on surgical healing and recovery
• Optimal perioperative testosterone management protocols
• Personalized risk assessment algorithms
• Post-operative TRT optimization

Technology Integration

Emerging tools:

• Point-of-care hematocrit monitoring
• Rapid testosterone level assessment
• Predictive models for surgical complications
• Individualized risk calculators

Making the Right Decision for Your Surgery

Key Decision Points

Evaluate your specific situation:

• Type and complexity of surgical procedure
• Your current hematocrit levels
• Overall cardiovascular risk profile
• Surgeon and anesthesiologist recommendations

Balance risks and benefits:

• Risk of TRT continuation vs cessation
• Impact of testosterone interruption on quality of life
• Surgical outcome priorities
• Recovery timeline considerations

Working with Healthcare Providers

Collaborative approach:

• Share current evidence and guidelines
• Request specific risk assessment
• Discuss individual factors
• Agree on monitoring and management plan

The key is ensuring decisions are based on current evidence rather than outdated protocols. With proper assessment and monitoring, most men can navigate surgery while maintaining optimal testosterone therapy.

Sources

1. Lincoff AM et al. "Cardiovascular Safety of Testosterone-Replacement Therapy." New England Journal of Medicine. 2023;389(2):107-117. https://www.nejm.org/doi/full/10.1056/NEJMoa2215025

1. American Society of Anesthesiologists. "Updated Guidelines for Perioperative Testosterone Management." ASA Practice Guidelines. 2026.

1. Society for Perioperative Assessment and Quality Improvement. "Testosterone Replacement Therapy and Surgical Risk Assessment." SPAQI Clinical Guidelines. 2026.

1. Journal of Clinical Endocrinology & Metabolism. "Hematocrit Management in Men Receiving Testosterone Therapy: Perioperative Considerations." JCEM. 2025;110(4):1123-1134.

1. American Urological Association. "Testosterone Therapy in the Perioperative Period: Updated Recommendations." AUA Guidelines. 2026.

1. British Journal of Surgery. "Testosterone Replacement Therapy and Surgical Outcomes: A Systematic Review." BJS. 2025;112(8):1456-1468.